

Ewa Janczewska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4984200/publications.pdf>

Version: 2024-02-01

65
papers

1,846
citations

566801

15
h-index

264894

42
g-index

65
all docs

65
docs citations

65
times ranked

2415
citing authors

#	ARTICLE	IF	CITATIONS
1	Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection. <i>Journal of Clinical Medicine</i> , 2022, 11, 389.	1.0	2
2	Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab605.	0.4	9
3	Significant Decrease in the Prevalence of Anxiety and Depression after Hepatitis C Eradication. <i>Journal of Clinical Medicine</i> , 2022, 11, 3044.	1.0	2
4	Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: EpiTer2 Study. <i>Liver International</i> , 2021, 41, 1789-1801.	1.9	10
5	Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study. <i>World Journal of Gastroenterology</i> , 2021, 27, 2177-2192.	1.4	5
6	Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. <i>Journal of Clinical Medicine</i> , 2021, 10, 3280.	1.0	13
7	Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy. <i>Cancers</i> , 2021, 13, 3694.	1.7	16
8	HCV resistance-associated substitutions following direct-acting antiviral therapy failure – Real-life data from Poland. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104949.	1.0	2
9	Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study. <i>Annals of Gastroenterology</i> , 2021, 34, 438-446.	0.4	2
10	1050. Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by 23valent Pneumococcal Polysaccharide Vaccine 6 Months Later in At-risk Adults Aged 18–49 Years (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors. <i>Open Forum Infectious Diseases</i> , 2021, 8, S616-S617.	0.4	1
11	Real life results of direct acting antiviral therapy for HCV infection in HIV–HCV-coinfected patients: EpiTer2 study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 762-769.	0.6	12
12	Real-world experience with Grazoprevir/Elbasvir in the treatment of previously “difficult to treat” patients infected with hepatitis C virus genotype 1 and 4. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1238-1246.	1.4	9
13	Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. <i>Advances in Medical Sciences</i> , 2020, 65, 12-17.	0.9	5
14	Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 36, 1944-1952.	1.4	9
15	Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfecting patients treated with DAA. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1045-1054.	2.0	12
16	Changes of patient profile, treatment effectiveness and safety during 4 years access to interferon-free therapy for hepatitis C virus infection. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 163-172.	0.3	14
17	Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters. <i>Clinical Microbiology and Infection</i> , 2019, 25, 513.e1-513.e6.	2.8	6
18	THU-197-Comparative effectiveness of 8 versus 12 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2019, 70, e250.	1.8	0

#	ARTICLE	IF	CITATIONS
19	THU-217-Low risk of HBV reactivation in a large European cohort of HBV/ HCV coinfecting patients treated with DAA. <i>Journal of Hepatology</i> , 2019, 70, e259.	1.8	1
20	Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study. <i>Clinical and Experimental Hepatology</i> , 2019, 5, 215-223.	0.6	1
21	THU-185-Effectiveness and safety of DAA-based treatment of hepatitis C patients with severe and end stage chronic kidney diseases-EpiTer-2 database analysis. <i>Journal of Hepatology</i> , 2019, 70, e243-e244.	1.8	0
22	THU-196-Efficacy of 8 versus 12-weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-weeks regimen in real world setting. <i>Journal of Hepatology</i> , 2019, 70, e249-e250.	1.8	0
23	JNJ4178 (AL335, Ombitasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA1. <i>Hepatology</i> , 2019, 69, 2349-2363.	3.6	6
24	Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-9.	0.8	12
25	Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8 week regimen in a real-world setting. <i>Archives of Medical Science</i> , 2019, , .	0.4	2
26	Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 93-100.	0.5	9
27	Treatment of <sc>HCV</sc> infection in Poland at the beginning of the interferon-free era—the EpiTer2 study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 661-669.	1.0	22
28	The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 580.	1.3	2
29	The efficacy of paritaprevir/ritonavir/ombitasvir + dasabuvir and ledipasvir/sofosbuvir is similar in patients who failed interferon-based treatment with first generation protease inhibitors. <i>Journal of Hepatology</i> , 2018, 68, S277.	1.8	0
30	Real world experience with twelve weeks of therapy without ribavirin in genotype 1 HCV infected compensated cirrhotics. <i>Journal of Hepatology</i> , 2018, 68, S296-S297.	1.8	0
31	Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in the AMBER, real-world experience study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1298-1305.	1.0	19
32	Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience. <i>Hepatitis Monthly</i> , 2018, 18, .	0.1	2
33	Simeprevir with peginterferon ± 2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study. <i>BMC Infectious Diseases</i> , 2017, 17, 389.	1.3	1
34	Effectiveness and safety of ledipasvir/sofosbuvir ± ribavirin in the treatment of HCV infection: The real-world HARVEST study. <i>Advances in Medical Sciences</i> , 2017, 62, 387-392.	0.9	23
35	Seladelpar (MBX-8025), a selective PPAR-γ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 716-726.	3.7	126
36	China's growing contribution to sepsis research from 1984 to 2014. <i>Medicine (United States)</i> , 2017, 96, e7275.	0.4	10

#	ARTICLE	IF	CITATIONS
37	Bioinformatics analysis of key genes and pathways for hepatocellular carcinoma transformed from cirrhosis. <i>Medicine (United States)</i> , 2017, 96, e6938.	0.4	29
38	Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study. <i>Clinical and Experimental Hepatology</i> , 2016, 4, 138-143.	0.6	16
39	Prevalence of HCV genotypes in Poland – the EpiTer study. <i>Clinical and Experimental Hepatology</i> , 2016, 4, 144-148.	0.6	18
40	Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in hepatitis C: AMBER study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 946-956.	1.9	82
41	Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. <i>Journal of Hepatology</i> , 2016, 64, 19-28.	1.8	60
42	Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. <i>World Journal of Gastroenterology</i> , 2016, 22, 3418-3431.	1.4	17
43	P0842 : Malachite-I: Phase 3B Trial of ombitasvir/paritaprevir/r and dasabuvir +/± ribavirin or telaprevir + peginterferon/ribavirin in treatment-naïve adults with HCV genotype 1. <i>Journal of Hepatology</i> , 2015, 62, S653-S654.	1.8	2
44	Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis. <i>Medicine (United States)</i> , 2014, 93, 1000-1007.	0.4	0
45	P0847 : Malachite-II: Phase 3b trial of ombitasvir/paritaprevir/r and dasabuvir + ribavirin or telaprevir + peginterferon/ribavirin in peginterferon/ribavirin treatment-experienced adults with HCV genotype 1. <i>Journal of Hepatology</i> , 2015, 62, S656-S657.	1.8	8
46	P1169 EFFECT OF PEGYLATED INTERFERON OR RIBAVIRIN DOSE REDUCTION DURING TELAPREVIR BASED THERAPY ON SVR12 IN NULL-RESPONDERS AND RELAPSEERS WITH ADVANCED LIVER FIBROSIS (ADVEX STUDY). <i>Journal of Hepatology</i> , 2014, 60, S474.	1.8	1
47	Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2014, 146, 744-753.e3.	0.6	42
48	ABT-450/Ombitasvir and Dasabuvir with or without Ribavirin for HCV. <i>New England Journal of Medicine</i> , 2014, 370, 1983-1992.	13.9	669
49	P1209 FACTORS INFLUENCING RENAL FUNCTION IN PATIENTS RECEIVING TELAPREVIR TWICE DAILY OR EVERY 8 HOURS: RESULTS FROM THE PHASE III OPTIMIZE STUDY. <i>Journal of Hepatology</i> , 2014, 60, S491.	1.8	0
50	Efficacy of Immunotherapy With TG4040, Peg-Interferon, and Ribavirin in a Phase 2 Study of Patients With Chronic HCV Infection. <i>Gastroenterology</i> , 2014, 147, 119-131.e3.	0.6	30
51	P1299 PEARL-III: 12 WEEKS OF ABT-450/R/267 + ABT-333 ACHIEVED SVR IN 99% OF 419 TREATMENT-NAIVE HCV GENOTYPE 1B-INFECTED ADULTS WITH OR WITHOUT RIBAVIRIN. <i>Journal of Hepatology</i> , 2014, 60, S527.	1.8	6
52	Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , 2014, 384, 414-426.	6.3	376
53	816 RIBAVIRIN DOSE REDUCTION DURING TELAPREVIR CONTAINING TRIPLE THERAPY DOES NOT AFFECT EARLY VIROLOGIC RESPONSE IN NON-RESPONDERS AND RELAPSEERS WITH ADVANCED LIVER FIBROSIS. <i>Journal of Hepatology</i> , 2013, 58, S334-S335.	1.8	1
54	919 ANEMIA AND ITS MANAGEMENT IN PATIENTS TREATED WITH TELAPREVIR TWICE DAILY VERSUS EVERY 8 HOURS IN THE PHASE III OPTIMIZE STUDY. <i>Journal of Hepatology</i> , 2013, 58, S379.	1.8	0

#	ARTICLE	IF	CITATIONS
55	826 SAFETY AND EFFICACY OF TWICE DAILY VERSUS EVERY 8 HOUR TELAPREVIR WITH PEGINTERFERON/RIBAVIRIN (PR) IN PATIENTS WITH CIRRHOSIS. <i>Journal of Hepatology</i> , 2013, 58, S338-S339.	1.8	0
56	798 EFFICACY OF TELAPREVIR DOSED TWICE DAILY VERSUS EVERY 8 HOURS BY IL28B GENOTYPE: RESULTS FROM THE PHASE III OPTIMIZE STUDY. <i>Journal of Hepatology</i> , 2013, 58, S326.	1.8	7
57	905 ADHERENCE WITH TELAPREVIR BID vs. q8h DOSING IN TREATMENT-NAÏVE HCV-INFECTED PATIENTS: RESULTS FROM THE PHASE III OPTIMIZE STUDY. <i>Journal of Hepatology</i> , 2013, 58, S373.	1.8	3
58	868 TREATMENT WITH TELAPREVIR-BASED THERAPY AFTER EXPOSURE TO PEG-IFN/RBV IN THE REALIZE STUDY: RESULTS FROM THE PHASE IIIB C219 ROLLOVER STUDY. <i>Journal of Hepatology</i> , 2013, 58, S356-S357.	1.8	0
59	1403 SIGNIFICANT IMPROVEMENT OF COMPLETE EVR IN HCVAC PHASE II CLINICAL TRIAL WHEN ADDING TG4040 THERAPEUTIC VACCINE TO PEGIFN±2A AND RIBAVIRIN. <i>Journal of Hepatology</i> , 2012, 56, S552.	1.8	6
60	Visfatin serum levels in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2010, 17, 254-260.	1.0	26
61	sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 79-90.	1.4	9
62	61 FACTORS INFLUENCING PROGRESSION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS OF THE 3-YEAR T2S-918-HCV STUDY WITH HCVE1 THERAPEUTIC VACCINATION. <i>Journal of Hepatology</i> , 2008, 48, S27-S28.	1.8	10
63	Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor- β 1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2006, 12, 961.	1.4	18
64	TGF-beta1 mRNA expression in liver biopsy specimens and TGF-beta1 serum levels in patients with chronic hepatitis C before and after antiviral therapy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2005, 30, 271-277.	0.7	25
65	Acromegaly and the risk of cancer. <i>Pathophysiology</i> , 2001, 8, 69-75.	1.0	10